Symposium

[GS02] Advanced approaches to fibrosis treatment by considering various organs

Mon. Mar 28, 2022 1:30 PM - 3:30 PM [Room B] Conference Room 131+132 (Bldg. 1: 3F)

Organizer: Naoki Dohi (Grad. Sch. Pharm. Sci., Univ. Shizuoka), Ayaha Yamamoto (Grad. Sch. Pharm., Osaka Univ.)

Fibrosis occurs in major organs, such as the heart, kidney, liver, and pancreas. The fibrotic organs eventually become dysfunctional. Fibrosis is also observed in cancer development and involved in the formation of tumor microenvironment. Fibrosis has so far been considered as an irreversible condition, having focused on the prevention rather than the treatment. However, several recent reports have shown that fibrotic state is reversible and proposed new therapeutic strategies for fibrosis treatment. Fibrosis is caused by excessive accumulation of extracellular matrix (ECM). Although ECM-secreting cells are different in different organs where fibrosis is organ-specifically induced, some mechanisms for fibrosis are likely common in these organs. Thus, understanding fibrosis in a cross-organ manner may be great benefit for the development of new therapeutic approaches. In this symposium, we present and discuss the latest results of our fibrosis research targeting ECM-producing cells in various organs, which allow us to deepen our understanding of fibrosis mechanism and to develop new approaches for fibrosis therapy.

+Add all to schedule

オーガナイザー挨拶：土肥直貴（静岡県大院薬） (1:30 PM - 1:35 PM)

1:35 PM - 1:57 PM

[GS02-1] OASIS in myofibroblasts contributes to the development of kidney fibrosis

○Ayaha Yamamoto¹, Masanori Obana¹, Yasushi Fujio¹ (1. Grad. Sch. Pharm., Osaka Univ.)

1:57 PM - 2:19 PM

[GS02-2] Identification of a sulfotransferase that promotes fibrosis

○Kotaro Kasai¹, Yuma Horii¹, Takanori Hironaka¹, Akiomi Nagasaka¹, Hitoshi Kurose¹, Michio Nakaya¹ (1. Grad. Sch. of Pharm., Kyushu Univ.)

2:19 PM - 2:41 PM

[GS02-3] Analysis of mechanisms underlying myofibroblastic CAF differentiation in a novel 3D cell culture model of the desmoplastic pancreatic cancer microenvironment

○Takuya Nakazawa^1,2, Hiroyoshi Y. Tanaka^3,4, Mitsunobu R. Kano^2,4 (1. Fac. Econ., Okayama Univ., 2. Grad. Sch. Interdis. Sci. Eng. Health Sys., Okayama Univ., 3. Grad. Sch. Med. Dent. Pharm. Sci., Okayama Univ., 4. Fac. Pharm. Sci., Okayama Univ.)

2:41 PM - 3:03 PM

[GS02-4] Development of technology to convert fibroblasts into endothelial cells for the treatment of fibrosis

○Tomoaki Kanbara¹, Kohei Izawa¹, Takefumi Doi¹, Yasushi Fujio¹, Yoshiaki Okada¹ (1. Grad. Sch. Pharm. Sci., Osaka Univ.)

3:03 PM - 3:25 PM

[GS02-5] Possibility of DIF-1, a small molecule which regulates the transdifferentiation of HSC, as a therapeutic agent for liver fibrosis

○Akira Ooka¹, Nanami Motohashi², Momoka Yamaguchi^1,2, Shin-ya Saito³, Tomohisa Ishikawa^1,2 (1. Grad. Sch. Pharm. Sci., Univ. Shizuoka, 2. Sch. Pharm. Sci., Univ. Shizuoka, 3. Fac. Vet. Med., Okayama Univ. Sci.)

総括：山本彩葉（阪大院薬） (3:25 PM - 3:30 PM)

Session information